Abstract: The present invention relates to a lithium composite oxide having improved stability and electrical characteristics as a positive electrode material by inhibiting an interfacial side reaction in the lithium composite oxide and improving the stability of a crystal structure and ion conductivity, and a lithium secondary battery including the same.

Abstract: An inorganic composite pigment capable of elevating ultraviolet (UV) protection, and a cosmetic composition including the same, in which the inorganic composite pigment includes a core part including a white pigment; and a surface coating material, which is coated on the surface of an external part of the core part, including an inorganic solution that includes the white pigment. Additionally, the white pigment is at least one kind selected from the group consisting of titanium dioxide, zinc oxide, cerium oxide, silica, talc, mica, and borosilicate. The inorganic composite pigment according to the present disclosure capable of elevating a UV protection undergoes surface modification of the pigment through a process of re-coating a white pigment on a white pigment with a high refractive index, thereby elevating the UV protection.

Abstract: The present invention relates to an LK8-Fc fusion protein, which has increased angiogenesis inhibitory activity and in vivo stability. More specifically, relates to an LK8-Fc fusion protein in which an LK8 protein having angiogenesis inhibitory activity is fused with the Fc region of human immunoglobulin IgG1, as well as a composition for treating cancer, which contains the fusion protein. The LK8-Fc fusion protein has not only angiogenesis inhibitory activity leading to anticancer and metastasis inhibitory activities, but also a very long in vivo half-life, and thus can be used as a more efficient and economic cancer therapeutic agent or cancer inhibitor.

Abstract: The present application discloses a method of reducing tumor growth that includes contacting the tumor with a tumor growth reducing effective amount of a composition comprising LK8 or LK68 protein or a functionally equivalent amino acid variant thereof and a pharmaceutically acceptable carrier thereof to a subject having tumor.

Abstract: The present application discloses a method of reducing tumor growth that includes contacting the tumor with a tumor growth reducing effective amount of a composition comprising LK8 or LK68 protein or a functionally equivalent amino acid variant thereof and a pharmaceutically acceptable carrier thereof to a subject having tumor.